Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update

Posted: March 25, 2022 at 2:21 am

- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study -

Read the original post:
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update

Related Posts